TNFSF10 and neoplasm: Despite favorable preclinical in vitro and in vivo results [37–39] of TRAIL as a single agent in first clinical trials, applying TRAIL has been disconcerting since only moderate overall anti-tumor activity has been achieved in patients with advanced malignancies [40].